# Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

> **NCT02311361** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Pancreatic Cancer
- Cancer of Pancreas
- Cancer of the Pancreas
- Pancreas Cancer

## Interventions

- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Tremelimumab
- **RADIATION:** Sterostatic body radiation therapy (SBRT)

## Key facts

- **NCT ID:** NCT02311361
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-25
- **Primary completion:** 2019-10-23
- **Final completion:** 2020-12-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02311361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02311361, "Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02311361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*